Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction on Friday, September 15th. The stock was sold at an average price of $69.50, for a total value of $208,500.00. Following the transaction, the insider now directly owns 191,583 shares of the company’s stock, valued at approximately $13,315,018.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Clovis Oncology, Inc. (NASDAQ CLVS) traded up 10.48% during mid-day trading on Monday, reaching $76.74. The company’s stock had a trading volume of 4,526,843 shares. The firm’s market capitalization is $3.75 billion. The firm has a 50-day moving average of $74.21 and a 200 day moving average of $68.78. Clovis Oncology, Inc. has a 1-year low of $25.50 and a 1-year high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.02). The company had revenue of $14.62 million during the quarter, compared to analysts’ expectations of $13.07 million. The company’s quarterly revenue was down 32.5% on a year-over-year basis. During the same period in the prior year, the company posted ($2.07) earnings per share. Equities analysts expect that Clovis Oncology, Inc. will post ($7.56) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of Stock” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/18/insider-selling-clovis-oncology-inc-clvs-insider-sells-3000-shares-of-stock.html.

Several research analysts have recently issued reports on CLVS shares. BidaskClub raised Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Monday, September 11th. Evercore ISI started coverage on Clovis Oncology in a research note on Wednesday, August 16th. They set an “in-line” rating and a $73.00 price target for the company. Royal Bank Of Canada started coverage on Clovis Oncology in a research note on Thursday. They set a “sector perform” rating and a $81.00 price target for the company. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating on shares of Clovis Oncology in a research note on Thursday, June 22nd. Nine equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $84.91.

Institutional investors have recently made changes to their positions in the stock. Phocas Financial Corp. purchased a new stake in Clovis Oncology in the 2nd quarter worth about $112,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Clovis Oncology by 71.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 758 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in Clovis Oncology by 160.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 1,168 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Clovis Oncology by 3.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after acquiring an additional 100 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Clovis Oncology in the 1st quarter worth about $185,000. 99.03% of the stock is owned by hedge funds and other institutional investors.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.